I wonder if ENTA can use this data to argue that the non-nuke has a minimal contribution to efficacy in pts with 1b (and aim for a higher royalty share)…
This is happening by default in Japan, where ABT-333 is not in the mix (#msg-91870291).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”